Posted by on Sep 12, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This phase 3 clinical trial will evaluate the safety and effectiveness of a copanlisib (BAY 80-6946) and rituximab (Rituxan) combination in treating patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by time to disease progression.

The details

Copanlisib is an inhibitor of phosphoinositide 3-kinase (PI3K), a protein that helps carry out signals for cell growth and division. Blocking this protein may stop the growth of cancerous B-cells, eventually leading to cell death. Rituximab is an immunotherapy, approved by the FDA, that uses the body’s own immune system to identify and kill cancerous B-cells. It is an antibody (a protein in the immune system) that binds to a protein found on B-cells, which alerts the immune system to attack.

This study will determine whether the combination of copanlisib and rituximab is effective in patients with relapsed disease. This study will examine the time to disease progression, disease response, overall survival, and adverse side effects over the course of 59 months.

 

Who are they looking for?

This trial is recruiting 514 patients with CD20 positive iNHL who have relapsed after at least 1 previous treatment. Patients who have previously received rituximab must be treatment free for at least 1 year, or 6 months if considered unfit for chemotherapy. Patients should have adequate blood laboratory values.

 Patients with lymphoma grade 3b or 4 are not eligible for treatment. Patients should not have HIV, or hepatitis B or C.

 

How will it work

Patients will be divided into two groups. One group will receive copanlisib and rituximab, while the other group will receive a placebo (substance with no active effect) and rituximab. Copanlisib or the placebo will be administered by injection on days 1, 8, and 15 of each 28-day cycle. Rituximab will be delivered intravenously (through IV into a vein) on days 1, 8, 15, and 22 during the first cycle, then on days 1, 3, 5, 7, and 9 of the following cycles.

Clinical trial locations

Locations near 20147, United States (Change):
Please enter zip/postal code and country to help us offer locations near you
Show only recruiting locations
Type:Interventional
Participants:450
Study ID:NCT02367040
Want personalized notifications? Get notified only when trials are matching for you.
(it's free)